---
document_datetime: 2024-07-22 13:11:13
document_pages: 10
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/trevicta-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: trevicta-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 5.5183915
conversion_datetime: 2025-12-15 00:56:58.473516
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
## Trevicta

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                            | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|--------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| N/0032               | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification) | 19/07/2024                          |                                             | Labelling and PL                 |           |
| IA/0031/G            | This was an application for a group of variations.                                               | 09/04/2024                          | n/a                                         |                                  |           |

1 Notifications  are issued for  type I variations  and Article  61(3) notifications  (unless part of a group including a type II variation  or extension  application  or a worksharing  application).  Opinions are  issued for all  other procedures.

2 A Commission  decision  (CD) is issued for procedures  that affect  the terms of the marketing  authorisation  (e.g.  summary of  product characteristics,  annex  II, labelling,  package  leaflet).  The CD is issued within two  months of  the opinion  for variations  falling  under the scope of  Article  23.1a(a)  of Regulation  (EU) No.  712/2012, or within  one year  for other procedures.

3 SmPC  (Summary  of Product Characteristics),  Annex  II, Labelling,  PL (Package  Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                    | and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place   |            |            |                        |                                   |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-----------------------------------|
| WS/2405            | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                            | 25/05/2023 | 10/05/2024 | SmPC, Labelling and PL |                                   |
| IG/1499            | C.I.11.a - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of wording agreed by the competent authority                                                                                                                                  | 21/03/2022 | n/a        |                        |                                   |
| PSUSA/2266/ 202106 | Periodic Safety Update EU Single assessment - paliperidone                                                                                                                                                                                                                                                                 | 10/02/2022 | n/a        |                        | PRAC Recommendation - maintenance |
| IB/0028            | B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)                                                                                                                                                                                     | 08/11/2021 | n/a        |                        |                                   |
| WS/1877            | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.                                                                                                                                                                              | 09/04/2021 | 29/04/2022 | SmPC and PL            |                                   |

<div style=\"page-break-after: always\"></div>

|           | - Change(s) in the SPC, Labelling or PL due to quality, preclinical, clinical or pharmacovigilance                                                                                                                                                                                                                                                |            |            |      | C.I.4 new data       |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|----------------------|
| IG/1257   | C.I.11.a - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of wording agreed by the competent authority                                                                                                                                                         | 21/07/2020 | n/a        |      |                      |
| WS/1833/G | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.b.z - Change in control of the AS - Other variation B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of | 25/06/2020 | n/a        |      | specification limits |
| R/0022    | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                           | 19/09/2019 | 14/11/2019 | SmPC |                      |
| WS/1638   | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.c.z - Container closure system of the AS - Other variation                                                                                                                                      | 11/07/2019 | n/a        |      |                      |
| IB/0019/G | This was an application for a group of variations.                                                                                                                                                                                                                                                                                                | 07/03/2019 | n/a        |      |                      |

<div style=\"page-break-after: always\"></div>

|           | B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation                                                                                                                                                                                                                                                                                                                      |            |     |                               |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-------------------------------|
| IB/0016/G | This was an application for a group of variations. B.I.z - Quality change - Active substance - Other variation B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting - Other variation                                                                                                                                                                                                                                                           | 07/03/2019 | n/a | material/intermediate/reagent |
| IG/1075/G | This was an application for a group of variations. B.I.b.2.c - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure for a reagent, which does not have a significant effect on the overall quality of the AS B.III.2.b - Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - Change to comply with an update of the relevant monograph of the Ph. Eur. or national pharmacopoeia of a | 28/02/2019 | n/a | Member State                  |
| IA/0020/G | This was an application for a group of variations. B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.b.1.b - Change in the specification parameters                                                                                                                                                                                                                                                         | 27/02/2019 | n/a |                               |

<div style=\"page-break-after: always\"></div>

|                    | and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits                                                                                                                                                                                                                                                                                                                                                                                                        |            |            |                        |                                                                                                                                                                                                                                                                                                                               |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/2266/ 201806 | Periodic Safety Update EU Single assessment - paliperidone                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 14/02/2019 | n/a        |                        | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                             |
| IA/0018/G          | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or | 06/02/2019 | n/a        |                        |                                                                                                                                                                                                                                                                                                                               |
| IA/0017            | B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter)                                                                                                                                                                                                                                                                                        | 06/02/2019 | n/a        |                        |                                                                                                                                                                                                                                                                                                                               |
| WS/1417/G          | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Update of sections 4.4 and 4.5 of the SmPC in order                                                                                                                                                                                                                                                                                                | 13/09/2018 | 12/12/2018 | SmPC, Labelling and PL | Caution is warranted in patients receiving both, psychostimulants (e.g., methylphenidate) and paliperidone concomitantly, as extrapyramidal symptoms could emerge when adjusting one or both medications. Gradual withdrawal of stimulant treatment is recommended. Catatonia has been introduced in the list of adverse drug |

<div style=\"page-break-after: always\"></div>

|         | to add information regarding concomitant use of paliperidone and risperidone with psychostimulants (in line with the CMDh recommendations for risperidone) and of section 4.8 of the SmPC to add catatonia as a new side-effect categorised as 'Rare'. The Package Leaflet is updated accordingly. The MAH took also the occasion to include editorial changes in the PI and to update the local representative for Ireland in the Package leaflet for Trevicta, Invega and Xeplion and Bulgaria for Risperidal Consta. The MAH also implemented the weekdays in section 5 of the annex IIIA for invega OPA blister according to the QRD guidance. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance   |            |            |             | reaction with a rare frequency.   |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-----------------------------------|
| WS/1359 | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Update of section 4.8 of the SmPC in order to include somnambulism and sleep-related eating disorder under a rare and not known frequency, respectively, after post marketing reports analysis. The Package Leaflet is updated accordingly. In addition, for INVEGA/XEPLION/TREVICTA minor editorial changes have been introduced and the details of the local                                                                                                                                                                                                                                                                                                                                                                        | 31/05/2018 | 12/12/2018 | SmPC and PL |                                   |

<div style=\"page-break-after: always\"></div>

|         | representatives in Portugal, Belgium Iceland, Slovenia, Netherlands and Luxembourg are updated in the Package Leaflet. An update is also proposed to the INVEGA Package Leaflet in section 2 to add a standard statement concerning sodium content according to the Annex to the European Commission guideline on 'Excipients in the labelling and package leaflet of medicinal products for human use'. Updated wording to align to the Excipients Guideline is also proposed for Risperdal Oral, together with removing the brand name (West Medimop) for the vial adaptors for Risperdal Consta. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data   |            |            |             |                                                                                                                                                                                                                                              |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0011 | Update of section 4.8 of the SmPC in order to update the safety information after assessment of study R092670-SCA-3004 (A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of Paliperidone Palmitate Evaluating Time to Relapse in Subjects With Schizoaffective Disorder). The Package Leaflet has been updated accordingly. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                       | 14/09/2017 | 12/12/2018 | SmPC and PL | There were no new adverse drug reactions following the assessment of study R092670-SCA-3004; only changes to frequencies of existing ADRs have been identified. For more information please refer to the Summary of Product Characteristics. |
| IB/0009 | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 17/09/2016 | 14/09/2017 | SmPC        |                                                                                                                                                                                                                                              |

<div style=\"page-break-after: always\"></div>

| X/0007/G           | This was an application for a group of variations. Annex I_2.(c) Change or addition of a new strength/potency A.2.a - Administrative change - Change in the (invented) name of the medicinal product for CAPs C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one C.I.7.b - Deletion of - a strength C.I.7.b - Deletion of - a strength C.I.7.b - Deletion of - a strength C.I.7.b - Deletion of - a strength C.I.7.b - Deletion of - a strength C.I.7.b - Deletion of - a strength     | 01/04/2016   | 26/05/2016   | SmPC, Annex II, Labelling and PL   | Please refer to Scientific Discussion Trevicta-H-4066-X- 0007-G-AR.                                                                                                                                                                                                                                                                                               |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/2266/ 201506 | Periodic Safety Update EU Single assessment - paliperidone                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 14/01/2016   | n/a          |                                    | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                 |
| WS/0760            | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Update of sections 4.4 and 4.8 of the SmPC in order to add a warning and update the safety information based on post-marketing experience on occurrence of hypersensitivity reactions in patients who have previously tolerated oral risperidone or paliperidone. The Package Leaflet is updated accordingly. In addition, the Worksharing applicant (WSA) took the opportunity to introduce minor editorial changes | 16/07/2015   | 13/04/2016   | SmPC and PL                        | Anaphylactic reactions in patients who have previously tolerated oral risperidone or oral paliperidone have been rarely reported during post marketing experience. If hypersensitivity reactions occur, discontinue use of paliperidone; initiate general supportive measures as clinically appropriate and monitor the patient until signs and symptoms resolve. |

<div style=\"page-break-after: always\"></div>

|           | Belgium and Luxemburg in the Package Leaflet. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                  |            |            |             |                       |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-----------------------|
| IG/0582/G | This was an application for a group of variations. C.I.11.a - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of wording agreed by the competent authority C.I.11.a - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of competent authority | 01/07/2015 | n/a        |             | wording agreed by the |
| WS/0700   | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                  | 25/06/2015 | 13/04/2016 | SmPC and PL |                       |
| IG/0549   | C.I.11.a - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of wording agreed by the competent authority                                                                                                                                                                                                                        | 29/04/2015 | n/a        |             |                       |
| IB/0003   | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following                                                                                                                                                                                                                                                                                                                   | 27/04/2015 | 13/04/2016 | SmPC        |                       |

<div style=\"page-break-after: always\"></div>

|         | assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH   |            |     |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| IG/0531 | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                              | 05/03/2015 | n/a |